Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Increase in Short Interest

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 140,100 shares, an increase of 846.6% from the September 15th total of 14,800 shares. Based on an average daily volume of 142,000 shares, the short-interest ratio is currently 1.0 days. Approximately 0.7% of the shares of the company are sold short.

Hedge Funds Weigh In On Xilio Therapeutics

An institutional investor recently raised its position in Xilio Therapeutics stock. Renaissance Technologies LLC lifted its holdings in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 18.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 295,000 shares of the company’s stock after buying an additional 45,554 shares during the quarter. Renaissance Technologies LLC owned about 0.80% of Xilio Therapeutics worth $280,000 at the end of the most recent quarter. Institutional investors and hedge funds own 54.29% of the company’s stock.

Xilio Therapeutics Trading Up 1.6 %

NASDAQ XLO opened at $0.80 on Friday. The business’s fifty day moving average is $0.82 and its 200-day moving average is $0.98. Xilio Therapeutics has a one year low of $0.49 and a one year high of $2.89.

Xilio Therapeutics (NASDAQ:XLO) last released its earnings results on Thursday, August 8th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). The business had revenue of $2.36 million for the quarter, compared to analysts’ expectations of $30.00 million. Equities analysts predict that Xilio Therapeutics will post -1.26 EPS for the current year.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.